Ustekinumab: differential use in psoriasis by Uhlenhake, Elizabeth E & Mehregan, David A
© 2011 Uhlenhake and Mehregan, publisher and licensee Dove Medical Press Ltd. This is an Open Access 
article which permits unrestricted noncommercial use, provided the original work is properly cited.
Clinical, Cosmetic and Investigational Dermatology 2011:4 93–99
Clinical, Cosmetic and Investigational Dermatology Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
93
RevIew
open access to scientific and medical research
Open Access Full Text Article
http://dx.doi.org/10.2147/CCID.S17917
Ustekinumab: differential use in psoriasis
elizabeth e Uhlenhake
David A Mehregan
wayne State University Department 
of Dermatology, wayne State 
University School of Medicine, 
Detroit, MI, USA
Correspondence: elizabeth e Uhlenhake 
Department of Dermatology, wayne 
State University School of Medicine, 
18100 Oakwood Blvd, Suite 300, 
Dearborn, MI 48124, USA 
Tel +1 313 429 7845 
Fax +1 313 429 7931 
email euhlenha@med.wayne.edu
Abstract: Chronic plaque psoriasis is a systemic disease affecting over 3% of the   population, 
and many patients are unsatisfied with their current treatment regimen. With advances in 
understanding of the pathophysiology of psoriasis, new therapeutic options are being developed. 
The newest of these agents, ustekinumab, offers patients rapid results and the convenience of 
four annual subcutaneous doses, with efficacy and safety profiles comparable with those of other 
biologics. However, ustekinumab has been on the market in the US for less than 2 years and 
will require years of extensive use before the full adverse event profile is fully understood. The 
purpose of this paper is to summarize the treatment options currently available for psoriasis, 
with an emphasis on ustekinumab in order to give prescribers an overview of the available data 
and allow them to make educated and informed prescribing decisions.
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Introduction
Psoriasis is a dermatologic condition characterized by plaques of scales and erythema 
that can involve virtually any area of the body. It is now recognized also as a systemic 
inflammatory disorder mediated by environmental and genetic factors, affecting 
2%–3% of the population, with 80% having mild-to-moderate disease.1,2
New breakthroughs in our understanding of the immunologic mechanisms 
underlying the pathogenesis of psoriasis are rapidly emerging. Research suggests 
that dysregulation occurs in the Th1 and Th17 T cells, resulting in persistent T cell 
  activation and high-level expression of certain proinflammatory cytokines, such as 
tumor necrosis factor alpha (TNF-α), interferon gamma (IFN-γ), interleukin (IL)-12, 
IL-17, and IL-23, as well as their receptors.3–7 As the etiological pathways of   psoriasis 
are   elucidated through basic science research, new clinical therapies are being 
  developed to   counteract these pathogenic targets. Biologic therapies have transformed 
the treatment of psoriasis and psoriatic arthritis in the last 10 years. While not for 
everyone, the biologics,   especially the TNF-α blockers, have certainly been shown 
to improve the lives of many patients with psoriasis, both physically and mentally.8–10 
However, their novel clinical efficacy comes at the price of unknown potential side 
effects that need to be studied and monitored closely.
Most recently, levels of both IL-12 and IL-23 have been found in higher concentrations 
in psoriatic plaques compared with normal skin, and genetic   polymorphisms in the gene 
encoding the shared p40 subunit of these cytokines have been linked to psoriasis.11–13 
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(Stelara®, Centocor Ortho   Biotech Services, Horsham, PA) 
which targets these cytokines specifically and has shown 
promising results in recalcitrant psoriasis.14–17 This paper 
gives a brief overview of therapeutic options for psoriasis, 
with a specific focus on ustekinumab, including its pharma-
cology, pharmacokinetics, efficacy, safety, and tolerability, as 
well as its specific role in the treatment of psoriasis.
Conventional and biologic 
therapeutics
There are various treatments available for psoriasis, each with 
their own unique benefits and risks. Likewise, there is great 
variety in the patient population with psoriasis, some having 
very little body surface area affected, some with extensive 
cutaneous as well as arthritis manifestations, and others with 
accompanying systemic comorbidities to consider, such as 
heart disease, hepatitis, history of cancer, or a neurological 
disorder. All of these factors must be taken into account in 
creating an appropriate therapeutic regimen.
Topical treatments, such as corticosteroids,   vitamin D 
  analogs, retinoids, and calcineurin inhibitors, are appropriate 
as monotherapy for localized disease and as adjunctive 
  therapy for resistant lesions   concurrently being treated with 
phototherapy or systemic medications.18   Moderate-to-severe 
psoriasis with more extensive or   disabling symptoms, such 
as deforming psoriatic arthritis, requires phototherapy or a 
systemic agent.
Phototherapy is generally the first-line treatment, but 
if not feasible or effective, systemic treatments using 
either   conventional oral agents or biologics are used. 
Phototherapy, specifically psoralen and ultraviolet A, nar-
row band ultraviolet B, and more recently excimer laser, 
is efficacious and   cost-effective, and lacks the systemic 
immunosuppression that occurs with traditional systemic 
agents and biologics, but requires more time commitment 
and disrupts the patient’s life.19 Photoaging and photocarcino-
genesis are long-term side effects that must also be discussed 
when considering light therapy.20–22
Traditional oral agents like methotrexate, acitretin, and 
cyclosporine may be considered as the next line of therapy 
based on their low cost, ease of oral administration, and the 
more long-term side effect information available. These 
agents require close patient monitoring, inclusive of liver 
and kidney function, blood pressure, cholesterol, and/or 
blood counts.23–25 Biologics are another option after failure 
of and/or intolerance to conventional systemic drugs or 
when a contraindication to the use of such drugs exists.26 
The first agents developed were the TNF-α inhibitors, 
ie, etanercept and infliximab, that have the most clinical data 
available regarding safety and efficacy. Despite the success 
of these biologics, there remains a population of patients 
with recalcitrant disease, which has led to the development 
of ustekinumab. This will be the focus of the remainder of 
this review.
Pharmacology and 
pharmacokinetics
Unlike other biologics, such as alefacept that target memory-
effector T lymphocytes, or TNF-α inhibitors, such as adali-
mumab, etanercept, and infliximab, ustekinumab is a human 
monoclonal antibody that binds to the shared p40 protein 
subunit of IL-12 and IL-23, preventing binding to their 
receptors and subsequent inhibition of downstream signaling 
(Table 1). Ustekinumab is absorbed and eliminated slowly, 
with an average half-life of 15–45 days.27 This long half-life 
enables convenient subcutaneous maintenance dosing once 
every 12 weeks, which is more appealing to patients than 
twice-weekly etanercept (half-life 102 hours) or every other 
week adalimumab (half-life 12–14 days).28,29 The simple 
subcutaneous injection is preferable to intramuscular injec-
tion of weekly alefacept (half-life 270 hours) and intravenous 
infliximab (half-life 8–9.5 days) infusions given as mainte-
nance every 6–8 weeks.30,31 Ustekinumab has fixed dosing 
based on body weight, with current dosage recommendations 
of 45 mg (for patients weighing , 100 kg) or 90 mg (for 
patients weighing . 100 kg) given by subcutaneous injec-
tion once at week 0 and again at week 4. This loading dose 
is followed by maintenance injection once every 12 weeks 
thereafter.32 This regimen has been shown to maintain efficacy 
for at least 1 year (Table 2).33
Efficacy, safety, and tolerability
Ustekinumab has been approved by the US Food and 
Drug Administration since September 2009 for adults 
with   moderate-to-severe plaque psoriasis. There have 
been a small number of randomized controlled studies 
of the efficacy and safety and fewer comparative studies 
comparing ustekinumab against other standard psoriasis 
therapies.
The first Phase I trial of ustekinumab involved 18 
patients with moderate-to-severe psoriasis who underwent 
intravenous administration of the drug and showed a 
sustained and dose-dependent improvement in Psoriasis 
Area and Severity Index (PASI), with 67% of subjects 
obtaining a 75% reduction in PASI (PASI 75) by week 16. 
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Table 1 General characteristics of biologic agents
Biologic  
agent
Mechanism  
of action
Dosage Route Efficacy based  
on Phase III 
trials  
(PASI 75)60
Black box 
warning
Cost (US$)58
Alefacept Human LFA-3 fusion 
protein preventing  
CD2 binding and 
reducing T helper  
cell function
15 mg every week given as 
intramuscular injection for 
12 weeks, with 12-week 
nontreatment period
Intramuscular 
injection
21% at week 14 None $1190 per 15 mg 
injection or $4760 
monthly for 3 months
Adalimumab Human monoclonal  
anti-TNF antibody
80 mg the first week,  
40 mg the second week,  
followed by 40 mg every  
other week given  
subcutaneously
Subcutaneous 
injection
71% at week 16 Serious 
infections, 
malignancy
$959.19 per 40 mg 
injection or $1918 
monthly
Infliximab Chimeric monoclonal 
anti-TNF antibody
5 mg/kg dose infusion schedule  
at weeks 0, 2, and 6, then  
every 6–8 weeks
Intravenous 
infusion
80% at week 10 Serious 
infections, 
malignancy,  
T cell 
lymphoma
Cost for 70 kg person 
is $3156 every  
8 weeks or  
$1578 monthly
etanercept Human p75 TNF-
receptor fusion  
protein
50 mg twice/week given 
subcutaneously for 3 months,  
then 50 mg once a week
Subcutaneous 
injection
3%–56.8%  
at week 12
Serious 
infections, 
malignancy
$498.71 per 50 mg 
injection or  
$1995 monthly
Ustekinumab Human monoclonal  
anti-p40 antibody
45 mg (patients ,100 kg) or  
90 mg (patients .100 kg)  
given by subcutaneous 
injection once at week 0  
then week 4, followed by  
injection every 12 weeks  
for maintenance
Subcutaneous 
injection
67.1%–75.7%  
at week 12
None $5595.60 per 45 mg 
or 90 mg injection or 
$1865 monthly  
after first year
Abbreviation: TNF, tumor necrosis factor.
after infusion, and maximal benefit appeared at 12 weeks 
for the majority of subjects.34 The second Phase I trial was a 
randomized, double-blind, placebo-controlled study evaluat-
ing a single subcutaneous administration of ustekinumab at 
doses of 0.27, 0.675, 1.35, or 2.7 mg/kg.35 In the 24-week 
study, 77% of all subjects on active treatment achieved 
PASI 75 between weeks 4 and 24 compared with 0% in 
the placebo group. As a part of the study, the participants 
agreed to skin lesion biopsies at baseline and 1 week after 
administration to assess the drug’s effect on the expression 
of proinflammatory cytokines. In subjects who had PASI 75 
through week 16, the expression of IFN-γ, IL-8, TNF-α, and 
IL-12p40 and IL-23p19 subunits was decreased compared 
with baseline.35
A 32-week, double-blind, placebo-controlled Phase II 
trial was performed in 320 patients randomized to receive 
one of four subcutaneous dosing regimens of ustekinumab 
(one 45 mg dose, one 90 mg dose, 4-weekly 45 mg doses, 
or 4-weekly 90 mg doses) or placebo. PASI 75 at week 
12 was achieved in 52%, 59%, 67%, 81%, and 2% of the 
aforementioned groups, respectively.36
Two subsequent randomized, double-blind, placebo-
controlled Phase III trials, known as Psoriasis Followed 
by Long Term Extension (PHOENIX) 1 and PHOENIX 2, 
assessed the long-term safety and efficacy of ustekinumab 
in large patient cohorts.37,38 The studies have a combined 
population of nearly 2000 patients and are set to last a total 
of 5 years. The PHOENIX 1 and PHOENIX 2 study designs 
had subjects randomly assigned to receive standard dosing of 
ustekinumab (45 mg or 90 mg subcutaneously at weeks 0 and 
4, and every 12 weeks thereafter) or placebo at weeks 0 and 
4, and subsequent crossover to ustekinumab at week 12, with 
half receiving 45 mg injections and the other half receiving 
90 mg injections every 12 weeks. Both trials found PASI 75 
improvement in more than 50% of both ustekinumab groups 
at week 12 (67.1% and 66.7% in the 45 mg group, and 66.4% 
and 75.7% in the 90 mg group vs 3.1% and 3.7% for placebo, 
respectively). Similar response rates after crossover at week 
12 from placebo to ustekinumab treatment were also found. 
Maximal efficacy was observed between weeks 20 and 24.
In the PHOENIX 1 trial, patients who achieved PASI 
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withdrawal from treatment at week 40. PASI 75 response 
was better maintained up to at least 1 year in those   receiving 
maintenance ustekinumab than in those withdrawn from 
treatment, suggesting that long-term therapy is necessary.37 
PHOENIX 2 examined dose intensification for those sub-
jects who did not respond fully (50%–75% improvement in 
PASI). At week 28, partial responders were re-randomized 
to   continue with their current dosing regimen every 
12 weeks or to increase the dose frequency to every 8 weeks. 
Approximately 67% of partial responders in the 90 mg group 
achieved PASI 75 after increasing their dosing frequency, 
but no clinical improvement was found in the 45 mg group 
with dose intensification. Partial responders tended to have 
higher body weight, more severe disease by physician’s 
global assessment (PGA), longer duration of skin disease, 
previous failure of biologic agent(s), and a higher incidence 
of psoriatic arthritis.38
Given the relatively short time for which ustekinumab 
has been clinically available, safety is a major concern for 
patients and physicians. However, there were no significant 
differences in adverse events observed between the treatment 
and placebo groups in the major Phase II and III trials.36–38 
Patients receiving maintenance ustekinumab therapy also did 
not experience increased rates of adverse events compared 
with patients in the randomized withdrawal group.38 Upper 
respiratory tract infections, nasopharyngitis, headache, and 
arthralgia were the most commonly reported adverse events. 
As with other immunosuppressants, there is concern about 
increased risk of infection with ustekinumab. No cases of 
tuberculosis, latent reactivation of tuberculosis, other myco-
bacterial infections, or Salmonella infections were observed. 
However, cellulitis and herpes zoster reactivation have both 
been reported with patients receiving ustekinumab.35–38 
Patients were screened for active tuberculosis before par-
ticipating in all studies, and although not mandatory, most 
clinicians also follow this practice before starting any bio-
logic agent.
A theoretical increase in susceptibility to malignancy was 
suggested in a mouse model where IL-12 was demonstrated 
to have antitumor activity.39–41 Thirty malignancies were 
reported in 26 patients treated with ustekinumab over 
100 weeks in the PHOENIX 2 trial, two of which were 
solid tumors and the remaining 28 were cutaneous, with no 
malignancies reported in PHOENIX 1.37,38 One cutaneous 
malignancy was reported in the Phase II trial in the placebo 
group and two in the treatment groups, as well as a case of 
prostate cancer.36 No differences were observed in laboratory 
tests between active treatment and placebo groups, including 
liver function tests, fasting glucose, D dimer, or hemoglobin 
A1c levels.37,38
Cardiovascular risk has also been evaluated. In the 
  placebo-controlled portions of the Phase II and III 
studies, five major adverse cardiac events including 
myocardial infarction or stroke were reported in 1582 
ustekinumab-treated patients compared with no events in 
732 placebo-treated patients. All cardiac events occurred 
in patients with at least three established cardiovascular 
risk factors.36–38 Subsequent analysis of data from the 
Phase II and III trials show no increased risk of myocar-
dial infarction or stroke compared with the general US 
and psoriasis populations.42 This possible increased risk 
of cardiac events is complicated by the fact that psoriasis 
patients themselves have increased cardiovascular events 
even without treatment.43,44
A single-blind, head-to-head trial of etanercept and 
  ustekinumab in 903 patients with moderate-to-severe 
psoriasis was recently performed by the manufacturers of 
ustekinumab.45 Patients were assigned to receive ustekinumab 
either 45 mg or 90 mg at weeks 0 and 4 or high-dose etan-
ercept (50 mg twice weekly) for 12 weeks. Approximately 
67.5% patients receiving 45 mg ustekinumab, 73.8% receiv-
ing 90 mg ustekinumab, and 56.8% receiving etanercept 
Table 2 Summary of ustekinumab characteristics
Indication
 •  Moderate-to-severe psoriasis in patients 18 years and over
Mechanism of action
 •    Fully human monoclonal antibody targeting shared p40 subunit of 
IL-12 and IL-23, downregulating inflammatory cytokine cascade
Dosage
 •    45 mg (,100 kg) or 90 mg (.100 kg) injection at weeks 0 and 4, 
then maintenance therapy every 12 weeks
Administration route
 •  Subcutaneous injection
Mean time to peak serum concentration
 •  Approximately 12 days
Half-life
 •  20–24 days
Most frequent adverse events
 •    Upper respiratory tract infections, nasopharyngitis, headache, and 
arthralgia
Cost
 •    US$5595.60 per injection, first annual cost US$27,980 successive 
annual cost US$22,384
Efficacy
 •  PASI 75 at week 12 based on Phase III data 67.1%–75.7%
Contraindications
 •  Previous hypersensitivity reaction, active tuberculosis
Abbreviations: IL, interleukin; PASI 75, 75% reduction in the Psoriasis Area and 
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achieved PASI 75 at week 12. Those patients who did not 
respond to etanercept at week 12, defined as having PGA 
scores $3, received 90 mg ustekinumab at weeks 16 and 
20, and those patients who did not respond to ustekinumab 
received one additional dose at their original dosage at 
week 16.
A major flaw in this study was the use of two different 
outcome measures, ie, PASI 75 as the primary outcome 
and PGA to determine which patients did not respond to 
therapies. Of the 347 patients that received etanercept, 295 
(85.0%) were crossed over to receive ustekinumab based on 
a PGA score $3 (vs only 43.2% achieving less than PASI 
75), which is comparable with the 174 of the 209 (83.3%) 
patients receiving ustekinumab 45 mg and 270 of the 347 
(77.8%) receiving ustekinumab 90 mg for an additional 
time because of PGA scores $3.46 Once crossed over to 
ustekinumab, 40.4% achieved a PGA score #1, but no such 
data were presented for the group of nonresponders that 
received additional ustekinumab. The proportions of patients 
who had at least one adverse event were similar in all groups. 
The only statistically significant difference was in the number 
of injection site reactions, ie, 24.8% in the etanercept group 
and 4.3% and 3.7% in the ustekinumab 45 mg and 90 mg 
groups, respectively.45 Further studies are required to evaluate 
the more long-term tolerability and safety of ustekinumab 
in these patients.
Role in therapy
Many factors must be taken into account when developing 
a management plan for a patient with psoriasis, including 
the extent of cutaneous involvement and/or presence of 
systemic symptoms, convenience of therapy, expected results, 
likely duration of remission, cost, logistics of accessing 
therapy (ie, transportation to light therapy or administering 
biologics), insurance coverage, short-term and long-term 
safety concerns, and any comorbidities. Risks and benefits 
of treatment must be weighed because minor cutaneous 
involvement of plaque psoriasis with little impact on 
patient’s lifestyle is not appropriate for a treatment with side 
effects of possible infection, sepsis, malignancy, and heart 
failure, as are associated with any biologic agent. Those 
patients with moderate-to-severe psoriasis are suited more 
for these products.
Given that there has been only one head-to-head trial com-
paring ustekinumab with other biologics, it is difficult to com-
ment on the order in which medications should be attempted. 
The target population will be further defined when addi-
tional data become available. Most importantly, side effect 
profiles must be reviewed in each patient’s case, as well as 
comorbidities that may preclude use of certain agents. Cost 
is another issue that must be factored in because the newer 
agents tend not to be covered by insurance companies, and 
most require evidence of prior failure of a cheaper alternative. 
In most clinical cases, insurance companies dictate which 
treatments clinicians can prescribe and in which order. In 
this regard, many physicians will keep ustekinumab as a last 
resort for patients with recalcitrant psoriasis not responsive 
to other agents, including anti-TNF drugs. With this in mind, 
a study in Denmark compared response rates in TNF-α 
inhibitor-naïve patients and TNF-α inhibitor-experienced 
patients after ustekinumab, and found that a lack of response 
to previous anti-TNF treatment did not impair the clinical 
response to ustekinumab, supporting other anecdotal reports 
of ustekinumab used for erythrodermic patients.47,48
Regarding psoriatic arthritis, a multicenter, randomized, 
double-blind, placebo-controlled Phase II trial of 146 patients 
was performed by Gottlieb et al to evaluate the efficacy and 
safety of ustekinumab. Subjects assigned to the ustekinumab 
group received 63 mg or 90 mg subcutaneously weekly for 
4 weeks (weeks 0–3) followed by placebo injections on weeks 
12 and 16; patients assigned to the control group received pla-
cebo injections at weeks 0–3, followed by ustekinumab 63 mg 
at weeks 12–16. The primary endpoint was American College 
of Rheumatology (ACR) 20 response at week 12, that corre-
sponds to a 20% improvement of disease criteria as determined 
by a rheumatologist. The ACR 20 score for the active treat-
ment group was higher (42%) than for placebo (14%) making 
ustekinumab a possible option for psoriatic arthritis.49
The effect and safety of ustekinumab has not yet been 
evaluated in patients under age 18 years or in pregnancy, 
although administration to cynomolgus monkeys demonstrated 
that ustekinumab does not have adverse effects on pre- or 
postnatal development.50,51 Rotational or combination therapies 
are often utilized in the management of psoriasis to exploit 
synergistic effects and minimize side effects with toxic doses. 
To date, there have been no trials examining the outcomes of 
combining traditional systemic agents or light therapy with 
ustekinumab, and there is only one small case series showing 
efficacy when combining ustekinumab with other systemics.52 
This is yet another area in need of further investigation.
Conclusion
Ustekinumab is the first agent of its class to be developed 
for clinical use, and it is difficult to predict its exact role in 
the treatment of psoriasis and psoriatic arthritis. Additional 
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from registries, databases, and pharmacovigilance activity, 
will further define the safety profile and target population 
for ustekinumab.53 However, ustekinumab has a convenient 
and rapid onset of action, making it an attractive option for 
patients. Increased compliance can be inferred, which also 
contributes to the appeal of this agent.54 Ustekinumab has 
also been shown to improve symptoms of anxiety, depres-
sion, and skin-related quality of life significantly, and can 
help to offset the US$4.5 billion lost annually from loss of 
work productivity due to psoriasis.55–57
Cost of medication must be considered because 
  ustekinumab is comparatively expensive at initiation of 
  therapy. Two doses are administered in the first 30 days at 
weeks 0 and 4, with an average wholesale price of US$11,192, 
and US$5596 every 12 weeks thereafter, yielding an annual 
drug cost of approximately US$27,980 in the first year for 
five doses and US$22,384 annually thereafter for four doses 
per year. This can be compared with the US$1995 monthly 
cost of etanercept, giving an annual cost of US$23,940.58 
Additionally, a recent cost analysis was performed,   showing 
that the cost per responder was around US$17,842 for usteki-
numab vs US$20,007 for etanercept.59 These data suggest 
that ustekinumab may actually save money in the long-term 
compared with other biologics. Given all the data thus far on 
ustekinumab, careful judgment by the clinician and patient, 
with consideration of risks and benefits, is required to opti-
mize efficacy and safety.
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